Drugs / TX200-TR101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04817774 | Mar 2021 → Jul 2024 | end stage renal failure, transplant rejection | Sangamo Therapeutics | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TX200-TR101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04817774 ↗ |
| Modality | Cell therapy | “Treg cells (CD4+/CD45RA+/CD25+/CD127low/neg) that have been ex vivo expanded and transduced with a lentiviral vector” NCT04817774 ↗ |
| Route | Intravenous | “via an IV infusion” NCT04817774 ↗ |
| Target | HLA-A | “a CAR to recognize HLA-A\*02” NCT04817774 ↗ |